达帕格利弗洛辛在儿童心力衰竭中降低射出分数 - 一项随机试点研究
Nabeel Valappil Faisal1, Praveen Arumugam1, Shivaprasad Pannasamudra Mohankumar1
1Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
Annals of pediatric cardiology
|February 23, 2026
概括
达帕格利弗洛辛在患有心力衰竭和减少喷射率 (HFrEF) 的儿童中显示出与标准护理相似的安全性. 这项试点研究发现,达帕格利弗洛辛和对照组之间的疗效结果没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖携带载体-2 抑制剂,如达帕格利弗洛辛,在患有心力衰竭 (HF) 的成年人中有效.
- 达帕格利弗洛辛在儿科HF群体中的安全性和有效性尚未得到充分证实.
- 扩张性心肌病是儿童心力衰竭的常见原因.
研究的目的:
- 评估达帕格利弗洛辛在患有心力衰竭和减少喷射率 (HFrEF) 的儿童中的安全性和有效性.
- 评估接受达帕格利弗洛辛的儿科患者的不良事件和临床结果.
主要方法:
- 一项随机对照试点研究,涉及20名患有扩张性心肌病和HFrEF的儿童 (年龄为1-12岁).
- 患者随机分配,接受达帕格利弗洛辛加标准治疗或仅接受标准治疗6个月.
- 主要结局:由HF恶化,HF住院和心血管死亡组成的组合. 二次结果:不良事件,NT-proBNP水平和功能类.
主要成果:
- 主要综合结局发生在达帕格利弗洛辛组的11.1%和对照组的18.25% (P=0.58).
- 达帕格利弗洛辛组的两名患者经历过渡性前性急性损伤;轻度低血症在45%的患者中观察到,没有显著的群体差异.
- 在达帕格利弗洛辛组中没有发生酸性或尿路感染. 两组都在NT-proBNP和功能类方面有所改善.
结论:
- 达帕格利弗洛辛在患有HFrEF的儿童中通常耐受良好,其安全性与对照组相比较.
- 在这项试点研究中,在儿科HFrEF患者中,达帕格利弗洛辛与标准治疗之间的疗效结果没有发现统计学上显著的差异.
- 需要进一步的研究来证实达帕格利弗洛辛在儿童心力衰竭中的长期安全性和有效性.
更多相关视频
05:18Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
89
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.8K
相关概念视频
01:30Heart Failure V: Medical Management
399
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
399
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
303
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
303
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
30
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
30
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
359
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
359
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
353
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276